Search research articles
Contact Us
Filters
Showing results (1-10 of 4) with videos related to
Page
of 1
Sort By:
Journal of Neuroimmunology
|
March 10, 2023
Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis
Sai Nagaratnam, Nimalan Harinesan, Rajiv Wijesinghe, et al.
Journal of Hepatology
|
July 8, 2015
Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders
Cameron J McDonald, Lesa Ostini, Daniel F Wallace, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Elizabeth A Richey, E Alison Lyons, Jonathan R Nebeker, et al.
Blood
|
August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
Charles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 4) with videos related to
Sort By:
Page
of 1
Journal of Neuroimmunology
|
March 10, 2023
Painless progressive mononeuritis multiplex secondary to AML associated neuroleukemiosis
Sai Nagaratnam, Nimalan Harinesan, Rajiv Wijesinghe, et al.
Journal of Hepatology
|
July 8, 2015
Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders
Cameron J McDonald, Lesa Ostini, Daniel F Wallace, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 29, 2009
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
Elizabeth A Richey, E Alison Lyons, Jonathan R Nebeker, et al.
Blood
|
August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
Charles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.
Page
of 1